Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
NCT04983407
Terminated
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive batiraxcept, nab-paclitaxel, and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerabil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: UCLA Health, Santa Monica, California
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04729608
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Disney Family Cancer Center, Burbank, California +6 locations
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
NCT04247126
Completed
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Conditions: Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
Register for Updates
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04329949
Terminated
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Site #171, Duarte, California +1 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935
Completed
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Stanford University Medical Center, Palo Alto, California
Conditions: Triple-negative Breast Cancer
Register for Updates
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
NCT03748134
Completed
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilim... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/22/2023
Locations: St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center, Anaheim, California +1 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
NCT01522768
Completed
The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive esophagogastric cancer that started to get bigger despite previous treatment with trastuzumab. The doctors will also study the tumor to understand why it grew while on trastuzumab treatment and to see the effects afatinib and paclitaxel has on the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
NCT04189588
Completed
This study is designed to compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: St.Joseph Heritage Care, Napa, California +2 locations
Conditions: Oncology Patients Receiving Chemotherapy
Register for Updates
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02272790
Completed
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Gender:
FEMALE
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2023
Locations: Research Site, La Jolla, California +2 locations
Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Register for Updates
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03611556
Completed
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
09/08/2023
Locations: Research Site, La Jolla, California
Conditions: Carcinoma, Metastatic Pancreatic Adenocarcinoma
Register for Updates
AO-176 in Multiple Solid Tumor Malignancies
NCT03834948
Completed
This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2023
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Solid Tumor
Register for Updates
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390
Completed
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California +63 locations
Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Register for Updates